Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide and the incidence and mortality rate are nearly identical in the United States. The Milan Criteria established thresholds of tumor size and number as predictors of optimum overall survival with liver transplant and changed the definitive treatment for HCC. However, after nearly two decades of experience two problems have emerged: post-transplant recurrence continues and an increasing number of patients exceed these size criteria. While tumor burden is an important prognostic factor, it remains limited in its ability to fully define underlying tumor biology and predict recurrence after transplant. Recognizing that tumor size and number are merely surrogate markers of tumor behavior, multiple centers have sought to expand these criteria and consider other oncologic and radiologic factors. Response to locoregional therapies may help to better determine tumor behavior and predict which patients might recur after transplant. Emerging analysis of tumor biology and genetics may also help to predict recurrence more accurately than size alone. Future selection of transplant candidates may be via molecular profiling or chronological imaging changes to identify those patients who would benefit most from the finite number of available grafts, while limiting recurrence after transplant.
Keywords: Hepatocellular carcinoma, transplant, prognosis.
Current Cancer Therapy Reviews
Title:Hepatocellular Carcinoma Outside of the Milan Criteria
Volume: 10 Issue: 3
Author(s): C. Anne Doughtie, Michael E. Egger, Kean O. Feyzeau, Christopher M. Jones, Michael R. Marvin, Kelly M. McMasters and Eric G. Davis
Affiliation:
Keywords: Hepatocellular carcinoma, transplant, prognosis.
Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide and the incidence and mortality rate are nearly identical in the United States. The Milan Criteria established thresholds of tumor size and number as predictors of optimum overall survival with liver transplant and changed the definitive treatment for HCC. However, after nearly two decades of experience two problems have emerged: post-transplant recurrence continues and an increasing number of patients exceed these size criteria. While tumor burden is an important prognostic factor, it remains limited in its ability to fully define underlying tumor biology and predict recurrence after transplant. Recognizing that tumor size and number are merely surrogate markers of tumor behavior, multiple centers have sought to expand these criteria and consider other oncologic and radiologic factors. Response to locoregional therapies may help to better determine tumor behavior and predict which patients might recur after transplant. Emerging analysis of tumor biology and genetics may also help to predict recurrence more accurately than size alone. Future selection of transplant candidates may be via molecular profiling or chronological imaging changes to identify those patients who would benefit most from the finite number of available grafts, while limiting recurrence after transplant.
Export Options
About this article
Cite this article as:
Doughtie C. Anne, E. Egger Michael, O. Feyzeau Kean, M. Jones Christopher, R. Marvin Michael, M. McMasters Kelly and G. Davis Eric, Hepatocellular Carcinoma Outside of the Milan Criteria, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212112046
DOI https://dx.doi.org/10.2174/157339471003150212112046 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis
Current Cancer Therapy Reviews Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Airway Stents: Current Practice and Future Directions
Current Respiratory Medicine Reviews Modulation of Mast Cell and Basophil Functions by Benzene Metabolites
Current Pharmaceutical Design Tumor Growth is Stimulated by Muscarinic Receptor Agonism: Role of Autoantibodies in Breast Cancer Patients
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets Polysaccharide-Protein Nanoassemblies: Novel Soft Materials for Biomedical and Biotechnological Applications
Current Protein & Peptide Science